Navigation Links
CHEST 2008: Featured abstracts
Date:10/28/2008

STATE TOBACCO CONTROL PROGRAM
(Tuesday, October 28, 2:30 PM EST)

New York residents who smoke are feeling the effects of the tobacco reduction strategies imposed by the New York Department of Health Tobacco Control Program (DOH-TCP). In a recent survey, researchers from North Shore-LIJ Center for Tobacco Control asked 277 New York residents attending a smoking cessation program why they intended to quit smoking. Of the participants, 33 percent of women and 8 percent of men cited greater social pressure to quit smoking, while 42 percent of women and 26 percent of men wanted to quit due to odor from tobacco use. Thirty percent of men and 17 percent of women reported wanting to quit because of pressure from their doctor, while 29 percent of men and 34 percent of women are quitting due to high cigarette prices. Furthermore, 16 percent of men and 11 percent of women cited quitting because there are fewer places where smoking is still permitted. Researchers conclude that the strategies imposed by the DOH-TCP, including increasing cigarette taxes, banning smoking at work, and educating health-care providers and the public about tobacco dependence, are having an impact on smokers in New York.

WEDNESDAY, OCTOBER 29

#6987
REMOTE PHYSICIAN CARE SAVES LIVES
(Wednesday, October 29, 10:30 AM EST)

Whether located in a neighboring hospital or in a clinic three states away, teleintensivists, physicians who remotely monitor and care for critically ill patients, are saving lives. Researchers from the University of Kansas, Kansas City, MO, compared 700 critically ill patients 1 year prior to remote telemonitoring implementation with 4,592 critically ill patients 2 years after telemonitoring implementation. They evaluated the severity-adjusted ICU and hospital length of stay (LOS) and ICU and hospital mortality. Results showed that remote teleintensivist care correlated with an improvement of severity-adjusted ICU and hospital LOS. Resu
'/>"/>

Contact: Jennifer Stawarz
jstawarz@chestnet.org
847-498-8306
American College of Chest Physicians
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. News briefs from the journal Chest, August 2007
2. Fat on chest and upper back increases risk of insulin resistance
3. U.S. Reps. Oberstar and Walz Discuss DM&E Railroad Expansion With Rochester, Minn. Leaders
4. Manchester researchers announce new methods of beating breast cancer
5. Eckert Seamans Announces Major Expansion in Philadelphia, West Chester and Harrisburg
6. Chest Compressions Key to Revised CPR Guidelines
7. Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia
8. Reflux Can Precipitate Chest Pain, Cough
9. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
10. News briefs from the November issue of Chest
11. Natures Baby Organics Announces Ah-Choo! Chest Rub
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10New study suggests the brain predicts what eyes in motion will see 55304 1New study suggests the brain predicts what eyes in motion will see 55304 2SRNL automakers to develop high performance wireless sensors networks 9693 1SRNL automakers to develop high performance wireless sensors networks 9693 2SRNL automakers to develop high performance wireless sensors networks 9693 3New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 1New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 2New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 3New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 4New Data Show ChloraPrep 28R 29 Significantly More Effective Than DuraPrep 28TM 29 and Povidone Iodine in Eliminating Bacteria From Skin Prior to Shou 55300 5